Please login to the form below

Not currently logged in
Email:
Password:

Clinigen acquires Idis for £225m

Acquisition makes them the global leader in unlicensed medicines

edit-clinigen-big 

Clinigen Group is to acquire unlicensed medicines supplier Idis for £225m.

The ethical unlicensed supply market is estimated to be worth in excess of $5bn and upon completion, Clinigen claims it will become the market leader. 

Peter George, CEO of Clinigen, commented: “This acquisition satisfies a number of our key strategic goals – achieving market leader position in the $5+billion unlicensed medicine supply sector and strengthening our leading position in the $2 billion clinical trial supply market.

“The acquisition will also accelerate our growth and give us a much better balanced portfolio of businesses, whilst extending our unique business model.”

Idis supplies unlicensed medicines predominantly on an exclusive basis through managed access programmes as well as on demand via its general access division.

George concluded: “The enlarged entity creates an incredibly exciting business with tremendous opportunities for growth. I am confident that, together with Idis, we have the right people to define and shape the unlicensed medicine supply market - an increasingly important health care sector for patients with unmet needs.”

Article by
Kirstie Pickering

27th April 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics